FDA orders COVID antibody makers Regeneron, Eli Lilly to track virus variants GSK kick-starts phase 3 Medicago-partnered COVID vaccine test House to vote later this week on bill to delay Medicare sequestration payment cuts AstraZeneca sells hundreds of thousands more doses of COVID-19 antibody combo to U.S. for $205M Emergent, amid gung-ho COVID-19 production push, eyes upgrade to Canadian vaccine plant: report One year of COVID: Vituity's CMO on how the vaccine changed everything UPDATED Coronavirus tracker: CVS to offer antibody tests at MinuteClinics in Massachusetts, Texas XPrize names winners of $6M COVID diagnostics competition Inflammatix nets $102M to advance its immune system tests for infectious diseases Featured Story | By Angus Liu Emerging coronavirus variants could pose threats to existing monoclonal antibodies and vaccines, and the FDA’s taken note, revising its emergency use authorizations for Eli Lilly’s and Regeneron’s drugs to require monitoring of—and potentially additional testing against—the new variants. read more |
| |
|---|
|
Top Stories By Ben Adams GlaxoSmithKline and Sanofi tripped up in a recent COVID-19 vaccine test, but the U.K. Big Pharma is hoping for better luck with its second partner Medicago. read more By Robert King The House plans to vote later this week on legislation to extend a moratorium on Medicare payment cuts installed by sequestration. read more By Fraiser Kansteiner AstraZeneca pledged 500,000 more doses of its experimental COVID-19 antibody drug, AZD7442, to the U.S. on Tuesday, bringing the country's total potential supply up to 700,000 doses in 2021. The government will pay $205 million for the extra stock, lifting the total U.S. investment in the development and supply of the treatment to around $726 million, AstraZeneca said. read more By Fraiser Kansteiner Emergent is in talks with the Canadian government to fund an expansion of its vaccine plant in Winnipeg, The Globe and Mail reports. The facility, which employs around 350, could eventually boast annual capacity for 100 million doses per year. read more By Tina Reed A week after getting his second dose of the COVID-19 vaccine, emergency department physician Gregg Miller and his wife popped a bottle of champagne they'd been saving to mark the occasion. It feels like the beginning of the end of the pandemic, he said. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Conor Hale Nine teams have been selected as the winners of XPrize’s $6 million COVID-19 testing competition, with the goal of providing affordable and accurate diagnostics to help ensure the safety of everyday activities. read more By Conor Hale Inflammatix secured $102 million in new financing to help commercialize its point-of-care diagnostics portfolio aimed at profiling a person’s immune response to quickly ascertain bacterial and viral infections and help curb potential antimicrobial resistance. read more |
